List of Microbiome Companies in United States - 150

16S Technologies delivers actionable, cost-effective and pain-free information using advanced DNA science to the oil and gas and industrial markets. Employing advanced DNA sequencing and proprietary data analytics, we offer a range of genomics diagnostics, biocide selection and consultancy services for microbial challenges faced by the oil and gas industry. In addition, 16S offers DNA-based oil and water tracers that have significant advantages when compared to legacy tracer technology. Specifically, DNA tracers are cheaper, more plentiful and not disproportionately affected by downhole environments. Please contact us directly to talk more about our tracer or biocorrosion application.

3BarBio offers increased profitability to discovery companies, bulk suppliers, and distributors by addressing the major hurdle to further adoption of biologics by designing innovative packaging to deliver viable microbes to the ag market. With its proprietary LiveMicrobe® Design. Develop. Deliver. process, 3Bar delivers on demand for partners around the world.

Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on leveraging host adaptive responses through gut-brain signaling for the treatment of metabolic and inflammatory diseases. The company has multiple programs in its pipeline and has received FDA orphan drug designation for its novel drug candidate for Prader-Willi syndrome.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.

AgBiomeis usingknowledge of the crop microbiome and an extensive network of field-sampling partners to build a proprietary microbial strain collection that is both diverse and large—larger, in fact, than the major public strain collections. Unlike many programs, which only use metagenomics surveys, the AgBiome platform is focused on true isolated microbial strains, which provideinsight into the genomic composition of crop-associated microbes. The company uses this collection as a resource for discovering new biologicals and trait genes.Existing microbial classification systems based on 16S rDNA sequences or other fingerprinting technologies are imprecise—microbes that are classified as ‘the same’ often differ by hundreds of genes. AgBiome uses proprietary algorithms based on whole genome sequence to classify organisms in their collection. This allows the company to measure the true diversity of plant-associated microbes at the gene level—and genes determine function and performance. The company has also applied our whole-genome methods to their straincollection.

AgriGro’s® formulations deliver plant nutrition along with a prebiotic concentrate, which significantly increases the growth of beneficial native microbial species. The company sells prebiotics for crops, livestock, gardening, golf, and wildlife. The company also makes a prebiotic formulation for treating organic waste or bio-solid residue.

Harvesting the power of Nature, Allied Microbiota develops advanced microbes to clean-up environmental contamination faster, more sustainably, and more cost-effectively than traditional remediation methods. Our products tackle the toughest contaminants like those from manufactured gas plants, chlorinated organics, and even emerging contaminants like per- and poly-fluoroalkyl substances (PFAS). We developed a heat-loving microbe called ThermO+ that breaks down contaminants at a fraction of the cost and significantly faster than traditional methods. Powered by heat and on oxygen, our microbes can clean difficult contaminants such as chlorinated compounds like polychlorinated biphenyls (PCBs), petroleum products, and dioxins from the soil, turning brownfields into greenfields. We don't bury the problem. We solve it. Site cleans ups can be expensive, but our technology makes this possible for companies, developers, and communities. We aim and strive to create cleaner, healthier, and productive areas around the world. Make Allied Microbiota your fast, affordable, and go-to solution for a cleaner tomorrow.

Alveolus Bio is a team of scientists, physicians, and innovators pioneering breakthrough FDA-approved therapeutics for lung diseases. Our pipeline includes preclinical stage live biotherapeutics for Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). Inhaled delivery effectively targets the distal regions of the lungs, bypassing first-pass metabolism and enhancing efficacy while reducing adverse effects, differentiating our drugs from other treatments.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

Since 2016, AnimalBiome has helped tens of thousands of pet parents and veterinarians monitor and improve the gut health, and overall health, of companion animals around the world. See how we can help your pet or veterinary practice at animalbiome.com or animalbiome.vet (veterinarians only).

Ansella Therapeutics is a specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes.

AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications.

Apton is a California-based biotechnology company that manufactures and supplies single-molecule detection and sequencing imaging systems for clinical applications.

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

ArkeaBio is a company focused on developing technology to reduce greenhouse gas emissions from the agricultural industry, specifically targeting livestock methane emissions. The company was founded on the premise that a simple vaccine could be a powerful tool in fighting climate change.

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle.

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

BIO-CAT provides the very latest enzyme technology and custom formulations. Founded in 1988, our extensive range of products, from single-to-multi-enzyme blends, service various industrial, food, agriculture and other commercial markets. BIO-CAT is an FSSC 22000 certified facility in Virginia featuring state-of-the-art laboratories for scientific research, product development and on-site quality testing to better serve customers. BIO-CAT Microbials is an innovator in the field of biological solutions for a broad range of emerging and existing markets and industries. BIO-CAT Microbials is a GMP certified facility and a division of BIO-CAT, utilizing the latest enzyme technology in combination with microbes to produce products that are pioneering, more effective and of the highest quality for our customers’ applications.

BioForm Solutions is a San Diego-based contract research organization providing services for the analysis of probiotics in the supplement, food and beverage, cosmetic, and agriculture markets. BioForm Solutions offers industry leading, cutting edge flow cytometry assays developed exclusively by the BioForm team. These assays offer a broad spectrum of solutions for the analysis of probiotic samples in most formulations and are supported by a dedicated staff having over 20 years experience in flow cytometry. We strive to improve our customer's probiotic-based products, including accurately enumerating the viability of probiotics, determining packaging effects, and shelf life evaluation. We are passionate about providing the highest quality services at an outstanding value, along with superior customer service and technical support.

BIOHM optimizes digestive health by combining good bacteria, good fungi and enzymes to break down digestive plaque, allowing for total gut balance. This allows BIOHM's 30 billion live active cultures to maintain, support, and promote the balance of the total microbiome in the digestive system.

Biolumen is a weight-loss and gut health company, on a mission to reverse the negative impact of the Western diet; like obesity, type 2 diabetes and autoimmune disorders. Biolumen's product, Monch Monch, is a highly functional cellulose matrix which entraps calories in the stomach.

OUR COMPANY BioMed Valley Discoveries, Inc., is a clinical stage biotechnology company with a mission to address unmet patient needs across a wide spectrum of diseases. Operating since 2007, BioMed Valley Discoveries advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, our stable long-term funding allows us to advance programs that may not fit within the model of more traditional clinical development groups. OUR APPROACH BioMed Valley Discoveries leverage several hundred experts at leading academic and clinical institutions to move projects forward in the early stages of clinical development. Our partners have a proven track record of scientific rigor and experience in efficient study execution. Our selection of development partners is based on our desire to address unmet patient needs and achieve critical development milestones as swiftly as possible. Through this approach, we endeavor to quickly answer scientific questions and determine next steps in the development process. OUR TEAM BioMed Valley Discoveries calls on the talents of a core leadership team of scientists who are focused, passionate, and committed to advancing new medical innovations to improve the lives of patients with difficult-to-treat diseases. Our team brings extensive experience from pharma, biotech, and academia. By utilizing unique advantages from each of these settings, BioMed Valley Discoveries creates a highly creative and functional drug development environment. We take a nimble and thoughtful approach to advancing programs with a focused sense of urgency, allowing for the most efficient path forward.

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Biopico Systems Inc is a leader in the emerging field of interacting multiple organ systems or microphysiological systems technology. This technology will accurately recapitulate human physiology by engineering physiological fluidic flow and organ microenvironment.

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs in Dravet syndrome; other rare epilepsies; Amyotrophic Lateral Sclerosis (ALS), a disease that causes nerve cells to die, which breaks the neural pathways, and causes extreme mobility loss over time; and neurodegenerative and cognitive disorders.

Transformation. It's a word we hear a lot—the moment when a discovery leads to an innovation that fundamentally changes our world. There's a backstory to transformation—one that takes place in labs and research facilities by people who work tirelessly for years to reach that a-ha moment. Cerillo understands the passion, tenacity and investment that come before transformation. Our technology is laser-focused on helping you achieve greater efficiency and agility in your research. But more than that, it's designed to illuminate possibility by letting you view the same problem from new angles. Stratus, our portable plate reader, is helping scientists anticipate and creatively solve human challenges from the palm of their hand, giving them the freedom to take their work out into the world. And that's just the beginning. Our team is committed to constant innovation in our lab to make discovery in your lab easier. Think of us as the proactive lab partner you didn't know you needed, clearing the way for you to reach that transformational moment that changes the world for good.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

ClostraBiois dedicated to understanding and treating food allergies and other diseases of the immune system. The company is discovering and developing new therapeutics that modulate the protective ability of the microbiome.

Founded in 2015 in Salem, Mass., and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, Commonwealth Diagnostics International (CDI) helps providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. CDI's expansive portfolio of non-invasive at-home hydrogen and methane breath tests supports the diagnosis and treatment of Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), as well as fructose malabsorption, lactose malabsorption, and sucrose malabsorption. Focused on patient-centric principles, CDI breath tests are easy-to-use, quick, and safe for patients and support meaningful GI health outcomes by helping steer each practitioner's approach to dietary modification, homeopathic remedies, nutritional supplementation, immune support, high-quality probiotics, and additional testing.

CosmosID provides award-winning, end-to-end microbiome solutions. They offer NGS, Metabolomics, Bioinformatics, as well as the world's most advanced microbiome analysis software, CosmosID-HUB: Microbiome. The HUB relies on validated databases and algorithms specifically designed for maximum sensitivity, precision and lowest false positive rates. Unlike other solutions, CosmosID delivers strain-level results – we understand that the biologically informative and actionable unit in microbiology is not a genus or species, but ultimately a strain and its unique genetic and metabolic properties. CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University Bloomberg School of Public Health. To learn more please visit www.cosmosid.com.

CryoXtract is a biobanking company that specializes in automated solutions for preserving biospecimen integrity and improving data quality.

DHMRI is a 501(c)(3) non-profit, contract research organization specializing in the provision of cutting-edge genomic and metabolomic research services and instrumentation essential to furthering scientific understanding in areas including human health, nutrition, immuno-oncology, plant and animal trait development, and microbiome studies.The organization leverages its expertise and world-leading facilities through scientific collaborations with researchers and other non-profit organizations, world-wide, to deliver advancements in theknowledge and understanding of human wellness, health and longevity.As part of its mandate, DHMRI also provides an integrated core laboratory serving the North Carolina Research Campus (NCRC) and North Carolina university researchers, with cutting edge technologies, and services.

DayTwo is leading the charge in personalized nutrition through cutting-edge microbiome analysis. Our mission is to empower individuals to take control of their health by understanding and optimizing their unique gut microbiome. About Us: We specialize in precision health through microbiome-based insights that drive personalized dietary recommendations. We decode the intricacies of the microbiome and translate it into practical solutions. Services: -Microbiome analysis for personalized nutrition optimization. -Predictive dietary recommendations based on individual microbiome composition. Why Choose Us: -Advanced technology: State-of-the-art sequencing methods (full shotgun) and proprietary algorithms -Supported by science: Microbiome insights combined with 25 years of diverse patient data, bolstered by research published in prestigious journals such as Nature, Cell, JAMA, and Diabetes Care -Largest collection of data: World's largest high-resolution sequenced data set of over 90,000 samples -Personalized approach: Recommendations based on each unique microbiome profile Join us on the journey to better health and unlock the potential of your microbiome with DayTwo. Connect with us to learn more!

DERMALA, Inc. is a pioneering consumer dermatology startup leveraging the power of the human microbiome and cutting-edge data analytics to develop innovative, patented, science-backed, and clinically validated solutions for a range of skin conditions including acne, eczema, and skin health & longevity.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

At Elanco, we work to improve the health of animals through innovative products and services for pets and farm animals around the world. As a global animal health company, we provide solutions that empower our customers to advance a vision of Food and Companionship Enriching Life. Since 1954, Elanco has committed to empowering veterinarians, farmers, and all those who care for animals with the tools they need to help animals live healthy lives. Healthier animals are the key to making our lives better - This is the fundamental belief uniting all global Elanco employees. That's why we are committed to the idea that our business can be a unique force for good for all in society. Through our Elanco Healthy Purpose™ framework of Environmental, Social and Governance (ESG) commitments, we focus on delivering sustainable solutions to advance the well-being of animals, people and the planet. This program also enables our employees around the world to take paid time off to make an impact as a volunteer, offering their time or talent to give back to our customers, causes and communities. #ElancoHealthyPurpose #WeAreElanco

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

Endure Biotherapeutics (“Endure Bio” ™) in San Diego, California, was founded by Professor Amir Zarrinpar MD, PhD, at the Zarrinpar Laboratory, UCSD. The company is developing engineered engraftable live biotherapeutics for gastrointestinal diseases by genetically engineering man’s native bacteria to express therapeutic compounds (such as anti-inflammatory cytokines). Unlike other GI focused microbiome companies, our biotherapeutics will be targeted to remain resident, delivering potentially curative solutions that endure the host environment.

Official LinkedIn page for Esperion. At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc. Community guidelines: https://bit.ly/3vLCGdO Certified Great Place To Work®

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Evvy is unlocking precision women's healthcare through novel, overlooked female biomarkers — starting with the vaginal microbiome. Backed by leading healthcare investors such as General Catalyst, Left Lane Capital, and LabCorp, the Evvy team includes leading OB/GYNs and vaginal microbiome researchers with decades of experience at organizations like UCSF, Stanford, Harvard, Cleveland Clinic, and more. Evvy is one of the fastest growing women's health companies in the US — enabling us to deliver innovative, high quality care while scaling novel R&D to unlock a new, data-driven future in women's health. Evvy's Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing to tell you what's up down there, why it matters, and what you can do about it. Evvy's larger platform is the first vaginal healthcare service to bring together state-of-the-art testing, precision clinical care, and 1:1 coaching to give women and people with vaginas the care they deserve. Through this platform, Evvy is building real-world datasets that can transform our understanding of complex female health conditions. Imagine a world where female health is finally understood: where risks are detected early and precisely; conditions are defined with specificity and nuance; and diseases are treated with personalization and care. That's the world that Evvy is pioneering.

ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.

"EzBiome, Inc. is a microbiome company promising the discovery of exciting new biology and transformative therapeutics through data- and database-driven microbial taxonomy, new bacterial species concept and standard, and the use of carefully curated and expert validated reference database that includes >3,000 new species. We cater world-class sample to discovery services on microbial identification, microbial genomics, microbiome bioinformatics, and database expertise for businesses worldwide for regulated and non-regulated applications to shorten the time for microbiota-based discovery and development of therapeutics and companion diagnostics for microbiome-related diseases."

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company’s lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn’s disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Flightpath Biosciences - We are scientists committed to advancing new therapies targeting pathogen-driven diseases Flightpath Biosciences uses advanced drug discovery tools to identify optimal antimicrobial therapeutic candidates to vastly improve drug targeting and safety, reduce off-target impacts on the microbiome, speed the time-to-market and reduce the risk of antibiotic resistance. In parallel, our data science and bioinformatics partners are working hard to understand host and microbiome genetics and transcriptomics to further define the impact of our drugs on the patient’s immune system, microbiome and overall health. We believe this will lead us to new data, novel discoveries and additional targeted therapeutic candidates.

Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.

The company offers products and services in:advanced probiotics and feed additivesgenetically engineered probioticsassays and screens of probiotics, andcustom probiotic fermentation.

GoodBelly is the pioneer of gut health dedicated to improving people's lives with intestinal balance, digestive wellbeing and immunity support when consumed daily through everyday efficacious foods, beverages and supplements. Founded in 2006 with a vision to bring probiotics to the mainstream with functional solutions reliant on the well-studied probiotic strains Lactobacillus Plantarum 299v (LP299V®), GoodBelly is headquartered in Boulder, CO and available at 20,000 stores nationwide in natural, specialty, conventional, mass and convenience retailers.

GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases.

Holobiome is building a platform to solve the complexities of the human gut microbiome, which is then used to deliver its potential to multiple marketplaces to improve human health. Our initial focus is on mapping and manipulating the gut-brain-axis via next generation probiotics.

The company is developing probiotics and enzymes that improve cattle health and digestive efficiency by eliminating methane.

Impello® Biosciences was founded on a simple premise: biostimulants make horticulture better for everyone. Our integrated solutions, ranging from microorganisms to other bioactive compounds, help farmers everywhere increase the quality and yield of every harvest. Impello addresses tough agricultural challenges with next-generation biotechnology to support a better, healthier, and more sustainable planet.

Indigo Ag improves farmer profitability, environmental sustainability, and consumer health through the use of nature-based and digital technologies. The company's core offerings – Carbon, Market+, and biotrinsic – integrate across the supply chain to optimize how the world's most impactful crops are produced, sourced, and distributed. Founded in 2013 with a mission of harnessing nature to help farmers sustainably feed the planet, today the company's technology connects stakeholders across the agricultural ecosystem to unlock sustainability and profitability benefits for all.

Infinant Health, Inc is a privately held company committed to changing the trajectory of human health, one baby at a time, through our deep understanding of infant nutrition and the gut microbiome. Years of proprietary research into the role of breast milk and its impact on human development led to our groundbreaking discovery of B. infantis EVC001, a natural bacterial strain foundational to infant immune health. Unfortunately, B. infantis had been almost completely eradicated from infants in developed countries due to unintended consequences of modern medicine such as feeding and birthing practices. Now, there is a way to change that. What we found is that EVC001, our specific strain of B. infantis, is essential in developing a healthy microbiome and supporting healthy immune system function. We took that learning and developed INF108, a next-generation strain developed to prevent necrotizing enterocolitis (NEC) in pre-term infants. We believe the greatest chance to impact future health begins early, right after birth—a once in a lifetime opportunity where rapid development and radical changes occur. By unlocking human nutrition's full potential through introducing beneficial bacteria during early infancy, we can help build a foundation for better health. Investors in Infinant Health include Cargill and Bill & Melinda Gates Foundation, among others.

Founded by Jennifer Doudna, the Innovative Genomics Institute advances genome engineering to cure disease and ensure food security.

Inocucor supports the ideals of the next Green Revolution with powerful natural biologicalproducts that reduce the need for chemicalinputs on farms and in greenhouses.

Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. The company makes phage that target E. coli, Salmonella, and Listeria in pet and human food.Intralytix has developed and is continuing to develop phage preparations for preventing and treating bacterial diseases of pets and other animals, including agriculturally-important animals. Other products include phage mixtures as probiotics.Intralytix’s is also developing phage preparations for treating infected wounds.

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging human-identical molecules as new medicines. Their initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells as well as the gut microbiome

At Intrinsyx Bio, we are commercializing 3 decades of the leading academic research in the plant microbiome. Our endophytic microbes cause crop plants, grasses, ornamental plants, and trees to fix Nitrogen (N2) directly from the atmosphere into ammonia which helps improve nutrient use efficiency, supplement synthetic fertilizer requirements, and increase chlorophyll. These microbes live in leaves, stems, roots and don't require a nodule. Our endophyte microbes also mobilize insoluble phosphorous (P2) from soil into roots, as well as increase drought and salt tolerances.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

Jarrow Formulas is a California-based formulator and supplier of nutritional supplement products including vitamins, minerals, probiotics, concentrates, and enzymes.

Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn't. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we're broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.

Developed a highly multiplexed imaging technology for microbial detection, providing unparalleled speed, breadth, and flexibility.

KBioBox is a Bioinformatics company that specializes in fast precision Off Target Analysis and Gene Edit BioDesign for genetic data.

Kemin Industries is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human health, food safety and protection of the global food supply chain. Kemin ingredients offer solutions across various industries including animal health, nutraceuticals, pet food, food technologies, crop technologies, textiles, aquaculture and animal vaccines. Serving customers in more than 120 countries, Kemin works each day to provide ingredients that feed a growing population and is committed to the quality, safety and efficacy of food, feed and health-related products. Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 3,000 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, India, Italy, Russia, San Marino, Singapore, South Africa and the United States.

Kibow® Biotech is a biotechnology company founded in 1997, based in suburban Philadelphia and specializing in the development and commercialization of scientifically-formulated and clinically-tested probiotic and prebiotic dietary supplements. Kibow® specializes in probiotic supplements for maintaining kidney health, supporting immunity, cardio health, digestive health, and general wellness. Established to help fight these rapidly growing health risks, Kibow® provides the highest quality non-drug dietary supplements at affordable prices. Mission Kibow's® mission is to address health needs by utilizing their expertise in proprietary probiotics and functional fibers with extensive scientific and clinical drug-like validation to produce top tier supplements. Vision Our Vision is to advance the welfare of people globally by providing superior probiotic supplements. We will achieve our vision by developing effective, safe, and scientifically proven probiotic formulations. Our products will also be economical and convenient to use. We have already developed several innovative products, and will continue to do so while adhering to our humanitarian and social values.

Koliber Biosciences is a biotechnology company that accelerates biomedical discoveries using machine learning and artificial intelligence.

Kula Bio champions sustainable, biological solutions for modern agriculture. We energize nitrogen-fixing microbes to produce organic fertilizer. By rewiring the energy flow from sun to soil, we're disrupting synthetic fertilizer to eliminate the division between affordable practices and stewardship of our land, sea and air. For career opportunities, please visit https://www.kulabio.com/careers

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.

Medical Diagnostic Laboratories, L.L.C. (MDL), founded in 1997, serves primarily as a reference laboratory for Polymerase Chain Reaction (PCR) based testing to physicians, laboratories and hospitals worldwide. MDL is a CLIA certified infectious disease laboratory with multiple state licenses specializing in PCR technology. Molecular diagnostic techniques, such as the PCR method, are considered to be the most sensitive and specific for the laboratory diagnosis of infectious diseases. MDL offers unique, non-invasive, highly stable specimen collection and transport platforms, such as the OneSwab®, UroSwab® and NasoSwab®. These platforms enable MDL to offer a variety of PCR based tests from a single swab with high sensitivity and specificity. MDL specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties valuable tailored diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections. For example, the unique testing MDL offers for the specialties of Urology and Gynecology enables the detection of multiple pathogens as well as certain drug resistance profiles from a single swab by PCR. MDL's primary focus is in the field of infectious disease testing for Urology, Obstetrics and Gynecology, Respiratory Infectious diseases, Vector-borne diseases, Mycology and Pharmacogenomics. MDL is comprised of experts in the fields of Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance and Oncology. In addition to developing and validating new clinical diagnostic tests, the Research and Development Department also publishes research projects in peer-reviewed journals, presents scientific information at international symposia, and performs contractual research work for major commercial, governmental, and academic organizations.

The MU Genomics and Bioinformatics cores provide centralized genomic, bioinformatic and biostatistical services to investigators at universities and colleges throughout the state. The Genomics Core currently provides five services to research programs and individual investigators:high throughput next generation sequencing (NGS) to support whole genome, whole exome, RNA-Seq, single cell RNA-Seq, microbiome and global chromatin and methylation studiesbiostatistical and bioinformatic support for NGS projectsaccess to DNA/RNA sequence analysis softwareautomated Sanger DNA sequencing, genotyping and RNA/DNA quality assessmentaccess to shared instrumentation such as plate readers, real time thermal cyclers, Agilent Bioanalyzers, fluorimeters, and spectrophotometers

MarvelBiome, Inc. is a biopharmaceutical company with a vision of harnessing the power of microbes for treating various human diseases.

MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market.

Mawi's innovative non-invasive and invasive biosample collection technologies are designed for room temperature transport and storage with OMICS in mind ... Less Sample, More Answers! Our Mission is to offer simple and easy to use tools for the collection and stabilization of an array of biological samples from the point of collection to processing in Genomics, Proteomics and metabolomics assays, including but not limited to: -Oral samples (e.g. buccal cells) -Whole Blood -Tissue - Mammalian Cells -Body fluids -Microbial samples from different sources (e.g. feces, urine, vaginal, skin, soil etc....) Mawi DNA Technologies' vision is to uphold sample integrity from anywhere in the world with innovative technology that promotes sample collection diversity.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

For over 60 years, MeriCal has provided custom manufacturing and packaging services to the dietary supplement industry. Our state-of-the-art facilities located in Southern California and Ogden, UT offer a wide range of capabilities from research and development to turn-key manufactured & packaged products. MeriCal offers innovative nutritional products for today's world. We have over 230 years of combined industry experience on our team, along with a world-class formulation team you can trust. We globally source clinically researched ingredients to custom formulate unique solutions that meet our customer's needs. Today, we are a leading manufacturer and packaging leader in the dietary supplement industry. MeriCal offers extensive knowledge in the formulation and manufacturing of gummies, tablets, capsules, chewables, and powders for any size business or brand. From simple contract work to developing market-driven solutions, MeriCal does it all. Our goal is to exceed our customer's expectations in every endeavor. MeriCal embraces the core values of team work, respect, honesty and courtesy. As part of our ongoing commitment to providing a positive and healthy work environment for all of our employees, MeriCal offers a wide variety of employee benefits, including medical, dental and vision insurance, life insurance, holiday pay, PTO and a 401(K) retirement plan.

Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures. For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics. Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.

Almost every factor that affects health – from genetics and the microbiome to disease and lifestyle – exerts its influence by altering metabolite levels in the body or other biological system. By producing the most accurate and comprehensive picture of the collection of metabolites, known as the metabolome, from a single biological sample, Metabolon can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of disease, medical intervention, diet or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers some of biology’s most difficult questions. Metabolon's unrivaled capability to look deep into the metabolome has enabled us to build the world’s largest library of compounds that currently includes 5,200+ total known molecules. Our proprietary Precision Metabolomics™ platform, combined with the world's most experienced metabolomics scientists, delivers biologic insights and identification of novel commercial opportunities for drug discovery and development, through clinical trials and life cycle management. Metabolon’s expertise is also accelerating research and product development for clients in academia, population health, consumer products, and nutrition industries. Founded in 2000 and based in Research Triangle Park, North Carolina, Metabolon has conducted more than 10,000 independent and collaborative studies, resulting in 2,000+ publications in leading peer-reviewed journals. For more information about our technology, products and services, please visit www.metabolon.com.

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

A 30 year green environmental biotechnology research, development and manufacturer of biological products providing solutions with a conscience, specializing in Bioremediation, Oil Production issues; Well Stimulation, Microbial Enhanced Oil Recovery, Paraffin and Scale control, Tank cleaning, Terminal services, and Frac Damage Repair , Soil and Groundwater Clean-up, Degradation of Food Processing Wastes, and Animal Waste Solutions. Our products are 100% safe and environmentally compatible, microbially based, approved by EPA & USDA for use in the environment and leave low carbon imprint. Our products have been used successfully for over 25 years here in the United States, and globally in Canada, Mexico, Ireland, China, Ecuador, Russia, Kazakhstan, Brazil, to name a few countries we serve. See us featured in NASA Spinoff 2010 for our work on International Space Station wastewater purification system http://www.sti.nasa.gov/tto/

Microbe Detectives, a WaterTrust business, harnesses the power of modern DNA technology to analyze water and wastewater systems in municipal, industrial and agriculture markets. We empower leaders in facilities, technology, and service with knowledge about their water systems that is unprecedented. This translates into improved protection of human health, capital assets, water resources, and the environment at reduced costs. The company is a 2014 graduate of the Water Council's BREW accelerator, winner of the 2015 Wisconsin Innovation Awards and 2017 WEF Gascoigne Award, host of the 2017 Microbiome Water Summit, and was selected to participate in the 2018 WEFTEC/BlueTech Research Innovation Showcase.

Fecal microbiota transplant (FMT) has been gaining traction among healthcare providers, researchers, and patients, with hundreds of clinical trials underway and compelling data on FMT benefits for a variety of medical conditions, far beyond its initial application for Clostridium difficile. However, existing FMT treatment methods are time consuming, costly, and sometimes invasive. The team at MicrobiomX recognized the opportunity to develop a scalable, safe, rapid FMT solution.

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX's work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

Overview: To provide “best in class” genomic services for supporting our partner’s R&D capabilities solutions in the agriculture (plant and animal), pharmaceutical and industrial biotech industries. Experience: MOgene was formed in 2004, by industry leaders in genomic research. Over the years, the experienced team at MOgene have established themselves a solid reputation within the industry as the “go to” genomics service provider for academic, government and industrial research groups and institutions. Multiple studies have been presented and published in leading scientific journals, based on the genomic services provided by MOgene. Providing Results: The scientists at MOgene have years of experience collaborating with scientists in multiple biotech industries to provide solutions for their research. There have been over 100 publications from both large and small research companies utilizing data from MOgene services. Specialties: PacBio Sequel, Illumina Next Gen Sequencing, MicroArrays, QuantiGene and ProCarta Multiplex Assays, Nucleic Acid Extraction, qPCR, Clinical assays utilizing Arrays and NGS, plus full bioinformatics capabilities.

As the world’s leading manufacturer and supplier of mycorrhizal soil inoculants, Mycorrhizal Applications is dedicated to sustainability by providing the agriculture, horticulture, landscaping, turf, and forestry industries with efficient and effective microbial-based biorational solutions. Mycorrhizal Applications researches and manufactures beneficial mycorrhizal fungi that greatly accelerate plant growth by increasing the surface absorbing area of roots as much as 50 times. This symbiotic fungus produces a healthier root system which requires fewer inputs such as nutrients and water and leads to optimal soil health, higher yields, increased plant stress resilience, and crop sustainability. Mission: At Mycorrhizal Applications, we harness the power and wisdom of natural systems to promote living soils and increase quality, productivity, and health in all industries involving soils, plants, and people. Visit our Careers Page for more info, and to view our current career opportunities: https://mycorrhizae.com/careers/

Founded in 1895, Nexira is a family owned company who built its reputation as the world leader in acacia gum. Today Nexira is a global leader in natural ingredients and botanical extracts for food, nutrition, and dietary supplements. Our ingredients are perfectly suitable for the formulation of clean label products. Nexira manufactures in France a wide range of natural ingredients with recognized health benefits, such as Fibregum™ an all-natural, organic and GMO-free source of soluble dietary fiber. Nexira's portfolio for food industry includes a large range of branded natural acacia gum ingredients with exceptional functional properties (Emulsifiers & stabilizers, coating agents, texturizers, encapsulating agents…). Nexira's portfolio for supplement industry includes premium nutraceuticals, strongly supported with scientific & marketing supports, for digestive health, weight management, sports nutrition, joint health and men & women’s health.

NorthStrive Biosciences Inc., a PMGC Holdings company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

Notitia ("NO-TEE-SHA") means "data" in Latin. We are a microbiome company that applies a data-driven approach to develop innovative products for the ecological restoration of a healthy gut microbiome.  Our mission is to promote health by protecting and/or restoring the Foundation Guild™ of the gut microbiome. Our vision is to maximize everyone's healthspan by keeping their gut microbiome to the healthiest possible status for the longest possible time. The work of Dr. Liping Zhao, co-founder of Notitia, shows that a healthy gut microbiome is dominated by a specific group of beneficial bacteria named the "Foundation Guild." The Foundation Guild™ not only produces beneficial compounds essential to human health but also creates an environment that can suppress the overgrowing pathogens. Restoration and maintenance of the Foundation Guild™ are fundamental to improve health and wellness in patients with unmet medical needs and the generally healthy population. Notitia has developed a revolutionary Foundation Guild™ R&D platform which consists of three technologies: identification, isolation & preservation, and nutritional formulas to support the Foundation Guild™ bacteria. Notitia has created several products based on the Foundation Guild™ R&D platform for patients as well as for the generally healthy population. Foundation Guild™ Wellness Program: a monthly subscription service that provides: 1. Guild:Plus microbiome nutrition 2. Guild:Health data tracking portal 3. Guild:Quest microbiome test kit 4. Guild:Save bio-banking 5. Guild:Pro personalized family-based probiotics. Foundation Guild™ Clinical Program: 1. NBT-NM108, a botanical drug for promoting the Foundation Guild, currently available in a phase 2 trial for COVID-19 and expanded access programs. Additional trials for MS, DKD, Cancer, and Parkinson's will be available by Dec 2021. 2. NBT-BM306, a live biotherapeutic product for restoring the Foundation Guild. Phase 1 trial will be available by Dec 2021.

NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological dysfunction. NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications

We make seriously sweet proteins that are changing the world, one bite at a time. Sweetness from protein—not sugar—is the breakthrough you’ve been waiting for. They’re good for your body and good for the planet, but it’s their amazing taste that will keep you coming back. The gut-friendly, diabetic-friendly, all flavor, no compromise win we all deserve. We’re a team of biologists, engineers, food-lovers, health advocates and environmentalists on a mission to transform the world with healthy sweetness. Come join us in building a sweeter future for all. Try our NEW Lemonade: 80% less sugar, no alternative sweeteners, & made with real fruit!🍋🍓

Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to receive FDA authorization to test a live bacterial therapeutic, and is a pioneer in the field of LBPs. Our proprietary approach identifies differences between healthy and disease-related microbiomes, and leverages beneficial microbes to treat problematic disruptions or ‘dysbioses’. Osel’s approach of repopulating the microbiome with beneficial bacteria helps restore healthy and protective microbiomes. The primary focus of our work is women’s health, with indications including recurrent urinary tract infections and bacterial vaginosis. Our secondary focus is disorders of the gastrointestinal tract. Our product pipeline is demonstrating exciting therapeutic potential, with two clinical stage products and ongoing clinical trials.

Our mission is to combat dysbiosis* in the human body. To that end, we aim to commercialize antimicrobial peptide therapies to safely restore balance to the gut's microbial flora and overcoming disease. P4 Microbiome was founded by Johns Hopkins University professors Phillip Phan and Jay Pasricha. The company took over the clinical development of P4M01 from the US Army in February of 2020. Together they recognized the immense potential of this discovery, not only for oral health, but also for solving dysbiosis in the GI tract. Beginning with our gingivitis indication, we will work our way down the gastrointestinal (GI) tract, addressing conditions including small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) by correcting the underlying dysbiosis that drives pathology. *Dysbiosis: A change in the microbial composition, especially in the GI tract, that causes imbalance between beneficial and potentially pathogenic bacteria.

Pando Nutrition is a company in the livestock production industry that develops next generation probiotics to accelerate the transition towards antibiotic-free production, fighting disease, enhancing growth, and improving nutrition for animals.

PanTheryx™ is the leading nutrition and biotechnology company committed to the global commercialization of bovine colostrum-based health and wellness solutions. From establishing ourselves as the world's premier supplier of colostrum, to driving cutting edge research, to commercializing novel solutions, we are dedicated to harnessing the power of nature's superfood to develop revolutionary approaches to human and animal health.

Parallel is a next-generation skin health company providing effective, targeted solutions powered by microbiome science, genomics, and machine learning. At Parallel, everything we do is grounded in science and innovation. We believe that the future is precision medicine and we believe that what we’re building is vital to that vision. Here, consumers and patients can access best-in-class expertise and clinical guidance, a personalized genomic assessment to understand their skin microbiome, as well as personalized, targeted microbiome skincare products and prescriptions (if needed). With one of the largest data sets in the world on the skin microbiome, a 10,000-deep bacterial library, and patents pending, Parallel was just honored by Fast Company as a "World Changing Idea."

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.

Phyla is a clinically-proven acne probiotic that uses breakthrough technology to only kill bad acne bacteria on your skin so your microbiome can flourish.

Many solutions to global threats such as climate change, disease and crop infestation can be found right beneath our feet. Microbes in the soil have proven potential to sequester carbon, improve crops, kill pests, reduce disease and more. Pluton Biosciences utilizes unique Micromining™ technology to discover novel microbes and create innovative solutions to address key sustainability challenges facing agriculture.

Prenexus Health is the exclusive manufacturer of the world's first high-fiber, sugarcane XOS prebiotic. Our fully integrated, organic supply chain ensures we are delivering the highest quality prebiotic ingredients available for food, beverage and dietary supplements. Our mission is to improve the health and wellness of individuals through the manufacturing of a high-quality, high-purity natural prebiotic ingredient grown and processed in the U.S., following sustainable environmental practices.

One of CNBC's 20 Hottest Startups of 2014, ProdermIQ is a personalized skin care startup delivering the first objective skin health measurement tool to the commercial, research and medical markets. ProdermIQ capitalizes on the convergence of personalized medicine, probiotic health benefits and next generation genetic analysis technologies to create a consumer-accessible testing and analytical platform with unsurpassed sensitivity and accuracy at detecting and characterizing the skin microbiome. The ProdermIQ SKINdex Skin Health Measurement tool provides consumers and skin health professionals with current skin health status as well as information that may improve or maintain a healthy skin environment. Our mission is to is to create healthy and beautiful skin by first understanding the underlying environment on the skin and then driving the development of the next generation of personalized skin care by empowering individuals and skin health professionals. Our vision of bringing personalized skincare to professionals and consumers has earned us the title of one of the top 50 innovative companies for 2014 by the Global Entrepreneurs Week - http://startupopen.com/gew50/

Promakhos Therapeutics is an Allston-based biotech startup founded in the spring of 2021. The company aims to develop curative therapies that restore the body's innate ability to fight inflammatory disorders. Promakhos Therapeutics focuses on creating therapies for autoinflammatory diseases based on a new and unexplored mechanism.

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

When you replace traditional leather chemicals with probiotic biochemicals, you lower costs and create a safer, more sustainable leather-making process.

Pylum is engineeringbacteriocinsand pyocins to target a variety ofpathogenicbacteria including E. coli, and K pneumoniae.Pyocins are similar to phage tail-like protein complexes and have bactericidal activity against strains ofPseudomonas.

Biotechnology and drug discovery developing microbiome therapeutics and direct to consumer products. Early stage company with a completion of a licensing agreement, a consumer product BioEsse, (A Probiotic Essensce for the Skin), in production, and medical indication for NDA and integrated development plan in progress.

science backed probiotics, prebiotics & bioactive botanicals for targeted restoration res makes physician developed & physician recommended supplements creator of the world's first respiratory probiotic resB!

Rise Therapeutics is developing targeted immunological-based biologics using a unique and proprietary oral delivery platform. The company develops unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity and cancer.

Scioto Biosciences is a clinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics. The companies treatment focuses on activating beneficial bacteria to promote healing.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts

SFA Therapeutics is a clinical stage start-up biotech company developing compounds discovered in human microbiome. This patented and proprietary platform is based on immuno-modulation of inflammatory factors derived from human gut microbiome. The technology is licensed from and supported by research at Temple University in Philadelphia. These products are a unique native immunotherapy platform with activity currently being investigated in cancer, liver, and auto-immune disease.

Helping immunotherapy realize its full potential to treat cancer - through the gut microbiome.

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA.

SFI Health are global leaders in developing & delivering human microbiome and cognitive natural health solutions that enable people to make informed health choices confidently. We believe we have the responsibility to bring proven natural health solutions to people’s healthcare needs. Our guiding principle is that our people act with integrity, courage and passion to: • Make a difference • Progress human quality of life • Act on learnings • Perform to promises made • Promote diversity

Solarea Bio is a clinical-stage biotechnology company in Cambridge, MA developing plant-based microbial solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The Solarea breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Using powerful genomic and bioinformatic tools, Solarea is mining its novel microbial strain collection to identify synergistic combinations of microbes and prebiotic plant fibers to develop solutions for patients suffering from inflammatory processes.

We are improving how we farm and what we eat by unleashing the natural power that exists in plants to create a more agile and resilient agriculture system.

Streck is an industry leader in the development and manufacturing of laboratory products. We make products that clinical laboratories use to ensure their instruments are accurately reporting patient results. In fact, Streck invented the first hematology reference controls and has developed many more firsts for the clinical laboratory. At the heart of the growth experienced by Streck during the past four decades is a healthcare industry constantly striving to provide better care to more people. Streck is at the center of helping clinical laboratories keep pace with the changes to which they must adapt. Hospitals, physician offices and research laboratories in every corner of the globe rely on Streck controls. The innovation and desire that drives Streck translates into unprecedented opportunity for every member of the Streck team – a team with a shared vision of quality and service.

The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohn's, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still aren't real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000's different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.

Leading with Science™, Synbiotic Health develops, clinically researches and markets Ecologically-Advanced™ probiotics for improved health. Using our novel discovery platforms IVS™ and IVE™ Synbiotic Health is pioneering a new category of Synergistic Synbiotics™— proprietary select combinations of Ecologically Advanced™ probiotics and prebiotics that change the microbiome to provide documented health benefits. Our science relies on understanding the ecological framework in the gut and how beneficial bacteria become established and compete with the resident microbes. At Synbiotic Health we consider the entire ecosystem, specific traits, and functions necessary for probiotics to support human health and outperform existing offerings in the market. Better Science for Better Health™

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit www.synlogictx.com

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit www.synlogictx.com

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours. Syntis is headquartered in Boston.

Taxa Technologies is a probiotics company that aims to revolutionize the understanding of microbiome engineering. They are focused on designing probiotics for personal care and enabling cheaper, faster, and better genetic engineering.

TECHLAB, Inc. is a leading developer and manufacturer of infectious disease diagnostics products worldwide. Since 1989, the company has offered a quality portfolio of diagnostic tests which now includes assays for C. difficile, respiratory pathogens, H. pylori, Campylobacter, Shiga toxin producing E. coli, protozoan parasites, and biomarkers of intestinal inflammation. TECHLAB is headquartered in Blacksburg, VA and manufactures its diagnostic tests in the United States at its state-of-the-art manufacturing facility in Radford, VA.

Tenza reprograms symbiotic bacteria from the human microbiome to administer medicines directly to the organs they naturally inhabit.

At Terrain Bio, we help RNA therapeutics companies design and build better RNA, faster. Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, we bring unparalleled speed and quality to RNA manufacturing.

Trace Genomics is a pioneer in the use of hi-definition genomics to activate the hidden insights in soil for healthier soils and a healthier planet. Through innovation in genomics, soil science and machine learning, Trace Genomics creates a pathway to deliver targeted database insights and actions at cost-speed-scale-accuracy for partners who are advancing modern farming solutions for a net-zero food production system. Where most companies deliver a partial picture, we provide a comprehensive and precise understanding of the soil’s composition—analyzing the soil’s biology, physical properties and chemistry. Trace Genomics has won several awards, including being selected as a 2020 Technology Pioneer by the World Economic Forum, Winner of FoodShot Global’s Innovating Soil 3.0 Challenge, Forbes Top 25 Most Innovative AgTech, THRIVE Top 50 AgTech, 2022 Global Cleantech top 100 start-ups and many more.

TULA is the leading probiotic skincare and wellness brand, offering innovative products powered by probiotics extracts and superfoods that are both clean & clinically effective. As a digitally native and social first brand, we engage our customers at every touchpoint to help them feel confident in their skin and make it easier to achieve a healthy balance, inside and out. Alongside TULA.com we retail in North America with ULTA Beauty, Sephora, Nordstrom, and Amazon as well as internationally with Mecca in AUS & NZ, SpaceNK in the UK, and TMall in China. We raised a Series A led by L Catterton, the largest consumer-focused private equity group in the world, and now operate independently within Procter & Gamble's Specialty Beauty division. Our team has experience in some of the top consumer startups and beauty companies, and our team is fully remote.

Turn Therapeutics® is a concept to approval pharmaceutical and medical device organization dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics® was founded with a goal of reducing antibiotic resistance through best in class acute and chronic wound care products. Through research and development, we have continued to uncover additional disease areas that our technology will serve. Our core mission is to leverage our expertise in drug delivery to create disruptive products for high need indications.

University at Buffalo Center for Entrepreneurial Leadership is an education institution that offers entrepreneurship and leadership development programs.

Varigen Biosciences Corporation is using metagenomics tools to investigatemicrobial diversity and develop natural products.

The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

From discovery to scale, Verb Biotics applies science, technology, and intentional development to deliver microbiome health solutions. Verb Biotics is a business-to-business ingredient supplier of pro, post, and synbiotics for food, beverage, and dietary supplement brands.

Versatope Therapeutics is an infectious disease company with two lead development programs and others at the preclinical stage. Versatope delivers immunity by customizing nano-size vesicles by using synthetic biology for biopharmaceutical applications.

Viomeanalyzes your microbiome and uses artificial intelligence to process the results and provide dietary advice.

Virtici is an innovation and product development company. We work with a growing ecosystem of world-class scientists, universities, businesses, and investment groups. Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients. Virtici is built on the foundation that life changing products are developed through innovation, hard work, and determination. Guided by our core values of innovation, integrity, dedication, teamwork and improvement, the Virtici team focuses on solving life’s biggest health challenges, creating and transforming scientific innovations into life changing medical products. We are always looking for extraordinary people with exceptional creativity and enthusiasm. Every employee contributes to shaping the future of the company. In our fast-paced and entrepreneurial environment, team members are expected to help solve big health-related problems.

Xeno Biosciences is pioneering a novel class of treatments targeting the human gut microbiome to address unmet needs in metabolic diseases.

Yakult is the world's leading probiotic beverage created in Japan in 1935. It is produced by Yakult Honsha Co., Ltd - the world's pioneer in probiotics. Today, Yakult is sold in more than 30 countries and regions around the world. Our company's portfolio includes a range of consumer, cosmetic and pharmaceutical products. For additional company information, please visit www.yakult.co.jp/english/. Science and research are the basis of our business. We have institutes in both Japan and Europe that are committed to discovering the endless applications for probiotics as well as the use of intestinal bacteria in human health globally. For more information about our science institutes, please visit www.yakult.co.jp/institute. Bringing Yakult to America is just one more step towards fulfilling Yakult's mission: to contribute to the health and happiness of every person around the world through the pursuit of excellence in life sciences and the study of microorganisms. We hope to achieve this goal while providing education to people about healthier living, developing community programs where we do business, and collaborating with medical doctors, dietitians and researchers. Yakult U.S.A. Inc. is a subsidiary of Yakult Honsha Co., Ltd. and is headquartered in Fountain Valley, CA. It supports Yakult's business in the United States and Canada. To contact our offices please email yakult@yakultusa.com.

ZBiotics is a synthetic biology company founded in 2016 and headquartered in San Francisco, California. The company bioengineers probiotic bacteria to create innovative products such as ZBiotics® Pre-Alcohol, a probiotic drink that breaks down the byproduct of alcohol responsible for negative effects.

Since its inception in 1994, Zymo Research has been proudly serving the scientific community by providing innovative, reliable, and high quality research tools at affordable prices. Our vision..."The Beauty of Science is to Make Things Simple"​ is now truer than ever. Whether it's epigenetics, DNA, RNA, E. coli, or yeast based research, our philosophy remains the same: To provide the highest quality products in the industry while ensuring they are both simple to use and reliable in their performance. Zymo Research is historically recognized for its innovation of high quality nucleic acid purification technologies. Under the branding DNA Purification Made Simple™ and RNA Purification Made Simple™, our technologies are pushing the limits of what is possible with nucleic acid isolation. As The Epigenetics Company™, Zymo Research has also received much attention for its rapidly expanding portfolio of epigenetics products and services. It is our objective to develop and provide the most comprehensive set of tools for DNA, RNA, and epigenetic research and analysis available today. Thousands of peer-reviewed scientific publications from researchers around the world feature our technologies. Through innovation, our scientists have made streamlined DNA methylation detection possible, pioneered the micro-elution column for DNA and RNA purification, developed the simplest and the most sophisticated methods for high-quality plasmid DNA purification, and patented the first RNA purification directly from Trizol without phase separation among many other leading technologies in the industry. At Zymo Research, we are committed to quality and guarantee that all of our products and service will meet and exceed your expectations. We pledge to be honest and responsible for everything we do with you. We will treat you as we would like to be treated. Together, we will build a brighter future.